Advertisement

Preoperative (“Neoadjuvant”) Chemotherapy in Locally Advanced Gastric Carcinoma

  • H. Wilke
  • P. Preusser
  • U. Fink
  • W. Achterrath
  • H.-J. Meyer
  • H. J. Schmoll
  • H. Poliwoda

Abstract

The prognosis for gastric carcinoma continues to be particularly unfavorable. Surgery can result in a cure or longer disease-free survival only in a small number of patients, since most gastric carcinomas are diagnosed when the tumor is in an advanced stage. More than 85% of all patients with newly diagnosed gastric carcinoma die from a nonresectable local tumor and/or distant metastases. For this reason, chemotherapy is the treatment of choice in cases of advanced gastric carcinoma, either alone or in combination with surgery and/or radiation therapy.

Keywords

Gastric Cancer Gastric Carcinoma Advanced Gastric Cancer Preoperative Chemotherapy Consolidation Chemotherapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Beretta G, Fraschini P, Labianca R, et al: The value of FAM polychemotherapy in advanced gastric carcinoma, abstract C-400. Proc ASCO 1982; 1: 103.Google Scholar
  2. 2.
    Beretta G, Fraschini P, Labianca R, et al: Weekly 5-fluorouracil (F) versus combination chemotherapy for advanced gastrointestinal carcinomas. A prospective study program, abstract C-367. Proc ASCO 1986; 5: 94.Google Scholar
  3. 3.
    Biran H, Sulkes A: A possible dose-response relationship in “FAM” chemotherapy for advanced gastric cancer, abstract C-515. Proc ASCO 1984; 3: 132.Google Scholar
  4. 4.
    Cartei G: 5-Fluorouracil, Adriamycin and Mitomycin C beim Magenkarzinom, in Nagel GA, Bach F, Bartsch HH (eds): Aktuelle Onkologie. Munich-Bern-Vienna, W. Zuckschwerdt, 1985, p 56.Google Scholar
  5. 5.
    Douglass HO Jr, Lavin PT, Goudsmit A, et al: An Eastern Cooperative Oncology Group evaluation of combinations of methyl-CCNU, mitomycin C, Adriamycin, and 5-fluorouracil in advanced measurable gastric cancer (EST 2277). J Clin Oncol 1984; 2: 1372.PubMedGoogle Scholar
  6. 6.
    Fornasiero A, Cartei G, Daniele O, et al: FAM2 regimen in disseminated gastric cancer. Tumori 1984; 70: 77.PubMedGoogle Scholar
  7. 7.
    Haas C, Oishi N, McDonald B, et al: Southwest Oncology Group phase II-III gastric cancer study: 5-fluorouracil, Adriamycin, and mitomycin C + vincristine (FAM vs V-FAM) compared to chlorozotocin (CZT), M-AMSA, and dihydroxyanthracenedione (DHAD) with unimpressive differences, abstract C-478. Proc ASCO 1983; 2: 122.Google Scholar
  8. 8.
    Haim N, Cohen Y, Honigman J, et al: Treatment of advanced gastric carcinoma with 5-fluorouracil, Adriamycin, and mitomycin C (FAM). Cancer Chemother Pharmacol 1982; 8: 277.PubMedCrossRefGoogle Scholar
  9. 9.
    Haim N, Epelbaum R, Cohen Y, et al: Further studies in the treatment of advanced gastric cancer by 5-fluorouracil, Adriamycin (doxorubicin), and mitomycin C (modified FAM). Cancer 1984; 54: 1999.Google Scholar
  10. 10.
    Kim NK: Chemotherapy of advanced gastric carcinoma with 5-fluorouracil, Adriamycin, mitomycin (FAM), and 5-fluorouracil, Adriamycin, cisplatin (FAP) combinations: experience in Korea, in Ogawa M, Muggia FM, Rozencweig M (eds): Adriamycin, Its Expanding Role in Cancer Treatment. Amsterdam, Excerpta Medica, 1984, p 137.Google Scholar
  11. 11.
    MacDonald JS, Schein PS, Woolley PV, et al: 5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination-chemotherapy for advanced gastric cancer. Ann Intern Med 1980; 93: 533.PubMedGoogle Scholar
  12. 12.
    Oshima K, Yamada T, Nonaka T, et al: Treatment of advanced GI cancer with 5-FU, Adriamycin, and mitomycin C (FAM). Proc 13th Intern Cancer Congr Seattle, 1982, abstract 695.Google Scholar
  13. 13.
    Pannettiere FJ, Haas C, McDonald B, et al: Drug combinations in the treatment of gastric adenocarcinoma: a randomized Southwest Oncology Group study. J Clin Oncol 1984; 2: 420.Google Scholar
  14. 14.
    The Gastrointestinal Tumor Study Group: Phase II-III chemotherapy studies in advanced gastric cancer. Cancer Treat Rep 1979; 63: 1871.Google Scholar
  15. 15.
    The Gastrointestinal Tumor Study Group: Randomized study of combination chemotherapy in unresectable gastric cancer. Cancer 1984; 53: 13.CrossRefGoogle Scholar
  16. 16.
    Levi JA, Dailey DN, Aroney RS: Improved combination chemotherapy in advanced gastric cancer. Br Med J 1979; 2: 1471.PubMedCrossRefGoogle Scholar
  17. 17.
    Levi JA, Fox RM, Tattersall MH, et al: Analysis of a prospective randomized comparison of doxorubicin versus 5-fluorouracil, doxorubicin, and BCNU in advanced gastric cancer: implications for future studies. J Clin Oncol 1986; 4: 1348.PubMedGoogle Scholar
  18. 18.
    Lopez M, Di Lauro L, Papaldo P, et al: Treatment of advanced measurable gastric carcinoma with 5-fluorouracil, Adriamycin, and BCNU. Oncology 1986; 43: 288.PubMedCrossRefGoogle Scholar
  19. 19.
    Lopez M, Perno CF, Di Lauro L, Papaldo P: 5-Fluorouracil, Adriamycin, BCNU (FAB) combination chemotherapy for advanced gastric cancer. Cancer Chemother Pharmacol 1984; 12: 194.PubMedCrossRefGoogle Scholar
  20. 20.
    Schnitzler G, Queisser W, Heim ME, et al: Phase III study of 5-FU and carmustine versus 5-FU, carmustine, and doxorubicin in advanced gastric cancer. Cancer Treat Rep 1986; 70: 477.PubMedGoogle Scholar
  21. 21.
    Cazap EL, Gisselbrecht C, Smith FP, et al: Phase II trials of 5-FU, doxorubicin, and cisplatin in advanced, measurable adenocarcinoma of the lung and stomach. Cancer Treat Rep 1986; 70: 781.PubMedGoogle Scholar
  22. 22.
    Figoli F, Galligioni E, Crivellari D, et al: Cisplatin (DDP) in combination with Adriamycin (A) and fluorouracil (F) (DAF) in advanced gastric cancer-a phase II study, abstract C-369. Proc ASCO 1986; 5: 95.Google Scholar
  23. 23.
    Moertel CG, Fleming T, O’Connell MJ, et al: A phase II study of combined 5-fluorouracil, doxorubicin, and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas. J Clin Oncol 1986; 4: 1053.PubMedGoogle Scholar
  24. 24.
    Moertel CG, Rubin J, O’Connell MJ, et al: A phase II study of combined 5-fluorouracil, doxorubicin, and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas. J Clin Oncol 1986; 4: 1053.PubMedGoogle Scholar
  25. 25.
    Robinson E, Haim N, Epelbaum R, et al: Phase II trials in the treatment of advanced gastric cancer, I- 5-fluorouracil, Adriamycin and mitomycin (FAM), II -cisplatin, Adriamycin and 5-fluorouracil (DAF), abstract C-300. Proc ASCO 1985; 4: 77.Google Scholar
  26. 26.
    Rougier P, Droz JP, Amiel JL, et al: Gastric carcinoma: a phase II trial of chemotherapy with association 5-fluorouracil (5 FU), Adriamycin (ADR) and cisplatin (DDP) (FAP protocol) in metastasized or inoperable patients. Preliminary results. Cancer Chemother Pharmacol 1985; 14 (suppl): 54.Google Scholar
  27. 27.
    Wagener DJT, Yap SH, Wobbes T, et al: Phase H trial of 5-fluorouracil, Adriamycin, and cisplatin (FAP) in advanced gastric cancer. Cancer Chemother Pharmacol 1985; 15: 86.PubMedCrossRefGoogle Scholar
  28. 28.
    Woolley P, Smith F, Estevez R, et al: A phase II trial of 5-FU, Adriamycin and cisplatin (FAP) in advanced gastric cancer, abstract C-481. Proc ASCO 1981; 455.Google Scholar
  29. 29.
    Preusser P, Wilke H, Achterrath W, et al: Advanced gastric carcinoma: a phase II study with etoposide (E), Adriamycin (A) and split course cisplatin (P) = EAP. Proc ASCO 1987; 6: 292.Google Scholar
  30. 30.
    Fujimoto S, Akao T, Itol B, et al: A study of survival in patients with stomach cancer treated by a combination of preoperative intra-arterial infusion therapy and surgery. Cancer 1976; 37: 1648.PubMedCrossRefGoogle Scholar
  31. 31.
    Nishioka B, Ouchi T, Watanabe S, et al: Follow-up study of preoperative oral administration of an antineoplastic agent as an adjuvant chemotherapy in gastric cancer. Gan To Kagaku Ryoho 1982; 9: 1427.PubMedGoogle Scholar
  32. 32.
    Stephens FO, Johnson AW, Crea P: Preoperative “basal” chemotherapy in the management of cancer of the stomach. Med J Aust 1984; 140: 143.PubMedGoogle Scholar
  33. 33.
    Jinnai D, Higashi H: Extended radical operation with preoperative chemotherapy for gastric cancer, in Hirayama T (ed): Cancer in Asia. Baltimore, University Park Press, 1976, p 111.Google Scholar
  34. 34.
    Klein HO: Preoperative chemotherapy in patients with gastric cancer. Prog Clin Biol Res 1985; 201: 283.PubMedGoogle Scholar
  35. 35.
    Bonatsos C, Aust J, Meisner D, et al: Preoperative chemotherapy for patients with locally advanced gastric cancer (abstract). Proc ASCO 1985; 4: 83.Google Scholar
  36. 36.
    Clark JR, Fallon BG, Frei III E: Induction chemotherapy as initial treatment for advanced head and neck cancer: a model for the multidisciplinary treatment of solid tumors, in DeVita VT, Hellman S, Rosenberg SA (eds): Important Advances in Oncology. Philadelphia, Lippincott, 1987, p 175.Google Scholar
  37. 37.
    Rosen G, Nirenberg A: Neoadjuvant chemotherapy for osteogenic sarcoma: a five-year follow-up (T-10) and preliminary report of new studies (T-12), in Wagener DJT, Blijham GH, Smeets JBE, et al (eds): Primary Chemotherapy in Cancer Medicine. New York, Alan R. Liss, 1985, p 39.Google Scholar
  38. 38.
    Advani SJ, Saiki TK, Swaroop S, et al: Anterior chemotherapy in esophageal cancer. Cancer 1985; 56: 1502.PubMedCrossRefGoogle Scholar
  39. 39.
    Goldie JH, Coldman AJ: A mathematical model for relating the sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979; 63: 1727.PubMedGoogle Scholar
  40. 40.
    Goldie JH, Coldman AJ: Quantitative model for multiple levels of drug resistance in clinical tumors. Cancer Treat Rep 1983; 67: 923.PubMedGoogle Scholar
  41. 41.
    Fisher D, Gunduz N, Saffer EA: Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. Cancer Res 1983; 43: 1488.PubMedGoogle Scholar
  42. 42.
    Van Putten LM: Optimal timing of adjuvant chemotherapy in mouse models, in Wagener DJT, Blijham GH, Smeets JBE, et al (eds): Primary Chemotherapy in Cancer Medicine. New York, Alan R. Liss, 1985, p 15.Google Scholar
  43. 43.
    Rubin P, Casarett GW: Clinical Radiation Pathology. Philadelphia, WB Saunders, 1968.Google Scholar
  44. 44.
    Reinhold HS, Buisman GH: Radiosensitivity of capillary endothelium. Br J Radiol 1973; 46: 54.PubMedCrossRefGoogle Scholar
  45. 45.
    Meyer HJ, Pichmayr R: Patterns of recurrence to therapeutic strategy in gastric cancer. Scand J Gastroenterol 1986; 22: 45.CrossRefGoogle Scholar
  46. 46.
    Trompke R, Grege A, Keser M: Zum natürlichen Verlauf des Magenkrebses. Bruns’ Beitr Klin Chir 1965; 211: 19.Google Scholar
  47. 47.
    Moertel CG: The natural history of advanced gastric cancer. Surg Gynec Obstet 1968; 126: 1071.PubMedGoogle Scholar

Copyright information

© Springer-Verlag New York, Inc. 1989

Authors and Affiliations

  • H. Wilke
  • P. Preusser
  • U. Fink
  • W. Achterrath
  • H.-J. Meyer
  • H. J. Schmoll
  • H. Poliwoda

There are no affiliations available

Personalised recommendations